ClinicalTrials.gg

Program

Bcl-2 Inhibitor LOXO-338

Also written as “LOXO-338”, “FCN-338 + Azacitidine” and “FCN-338 + erythromycin+ Ara-C”.

Its studies are mostly in Leukemia, Lymphocytic, Chronic, B-Cell · Leukemia, Myeloid, Acute, led by 2 companies.

Furthest: phase 2, since Feb 4, 20253 company-led studies, 2 open or runningNext primary completion: Dec 1, 2026 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Fosun Pharma22 open or runningphase 2since Feb 4, 2025Dec 10, 2020Dec 1, 2026phase 2 · NCT06858618
Eli Lilly10 open or runningphase 1since Aug 25, 2021Aug 25, 2021none ahead

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Dec 10, 2020First study: phase 1 study in Leukemia, Lymphocytic, Chronic, B-CellNew to Fosun PharmaFosun Pharma · NCT04682808 · 99 enrolled · China
  2. Aug 25, 2021Eli Lilly’s first study: phase 1 study in Leukemia, Lymphocytic, Chronic, B-CellNew to Eli LillyEli Lilly · NCT05024045 · 27 enrolled · United States, France, Italy and more
  3. Feb 4, 2025Phase 2 study in Leukemia, Myeloid, AcuteFosun Pharma · NCT06858618 · 47 enrolled · China

Ahead

  1. Dec 1, 2026Primary completion: phase 2 study in Leukemia, Myeloid, AcuteFosun Pharma · NCT06858618

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 3 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT06858618Leukemia, Myeloid, Acute · China2Active, not recruitingFosun PharmaDec 1, 202647
NCT05024045Leukemia, Lymphocytic, Chronic, B-Cell · United States, France, Italy and more1CompletedEli LillyJun 14, 202327
NCT04682808Leukemia, Lymphocytic, Chronic, B-Cell · China1Active, not recruitingFosun PharmaApr 28, 202499

How it is read

Names in the registry

  • “LOXO-338”, 1 entry
  • “FCN-338 + Azacitidine”, 1 entry
  • “FCN-338 + erythromycin+ Ara-C”, 1 entry
  • “FCN-338”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.